Bristol Myers Squibb reports news on its pharmaceutical portfolio across oncology, cardiovascular disease and immunology, including regulatory decisions, clinical trial data, commercial access programs and product collaborations. Company updates include Sotyktu (deucravacitinib), a selective TYK2 inhibitor approved in the European Union for active psoriatic arthritis, and Eliquis (apixaban), an oral anticoagulant marketed through the Bristol Myers Squibb-Pfizer alliance.
Recurring developments also cover quarterly financial results, investor conference participation, debt and capital-market activity, research collaborations in cardiovascular and precision-medicine programs, and community initiatives tied to multiple myeloma care. The company’s news flow combines product-specific regulatory milestones with broader disclosures on operating performance and pipeline partnerships.
Atrium Therapeutics (Nasdaq: RNA) announced it has earned a $15 million milestone payment from Bristol Myers Squibb (NYSE: BMY) after delivering a second lead RNA-based compound for an undisclosed cardiovascular indication under their global licensing and research collaboration.
According to Atrium Therapeutics, the BMS agreement includes eligibility for up to approximately $1.35 billion in research and development milestones, up to approximately $825 million in commercial milestones, and tiered royalties up to low double-digits on net sales. BMS will fund all future clinical development, regulatory and commercialization activities arising from the collaboration. Atrium is also advancing ATR 1072 for PRKAG2 syndrome into the Corventis Phase 1/2 trial following recent FDA IND clearance, and maintains a pipeline including ATR 1086 for PLN cardiomyopathy and two additional rare cardiomyopathy programs.
Bristol Myers Squibb (NYSE:BMY) will invest approximately $2.3 billion to build a new, state-of-the-art, multi-modal manufacturing campus at Generation Park in Houston, Texas. The roughly 600,000 square foot facility is intended to accelerate delivery of next-generation medicines and expand U.S. manufacturing capacity.
The campus is designed with modular, digitally advanced infrastructure to support multiple modalities, including small molecules, biologics and antibody-drug conjugates, from late-stage development through commercial launch. According to the company, the site will initially create nearly 500 skilled, well-paying jobs and is envisioned to grow in scale and capability over decades.
This project forms part of Bristol Myers Squibb’s broader $40 billion U.S. investment commitment over five years across research, technology and domestic manufacturing, and is expected to support about 2,000 construction and indirect jobs between 2027–2030, reinforcing American biopharmaceutical manufacturing and supply chain resilience.
Bristol Myers Squibb (NYSE: BMY) is expanding its AI compute infrastructure by deploying an NVIDIA DGX SuperPOD with DGX Vera Rubin NVL72 systems, which the company says will provide the most powerful and energy-efficient single-owned NVIDIA infrastructure in life sciences.
According to Bristol Myers Squibb, the Vera Rubin architecture can deliver up to ten times greater performance per megawatt than its predecessor, enabling larger and more complex AI workloads without proportional energy use. The platform will support AI-driven discovery across oncology, hematology, cardiovascular, immunology and neuroscience, underpin BMS’s “Predict First” approach, and power next-generation foundation models and agentic AI workflows using its proprietary data and NVIDIA’s BioNeMo capabilities.
Bristol Myers Squibb (NYSE: BMY) announced that the U.S. FDA has accepted its New Drug Application for mezigdomide, an oral CELMoD, in combination with carfilzomib and dexamethasone (MeziKd) for adults with relapsed or refractory multiple myeloma. The FDA assigned a PDUFA target action date of May 13, 2027.
The NDA is supported by Phase 3 SUCCESSOR-2 data, where MeziKd achieved a median progression-free survival of 18.0 months vs. 8.3 months for carfilzomib plus dexamethasone alone (hazard ratio 0.48; p<0.0001), corresponding to a 52% reduction in risk of disease progression or death. The analysis included 479 patients with a median age of 68 and a heavily pretreated population, most triple-class-exposed and refractory to anti-CD38 antibodies and lenalidomide. The safety profile of MeziKd was consistent with prior mezigdomide studies and the known profiles of the regimen’s components. According to Bristol Myers Squibb, mezigdomide is part of a broader targeted protein degradation platform, with additional ongoing trials, including the Phase 3 SUCCESSOR-1 study in RRMM.
Bristol Myers Squibb (NYSE:BMY) will report second quarter 2026 results on Thursday, July 30, 2026. A conference call with executives begins at 8:15 a.m. ET and will be available via live audio webcast on the company’s Investor Relations website, with replay access later.
Bristol Myers Squibb (NYSE:BMY) declared a quarterly dividend of $0.63 per share on its $0.10 par value common stock. The dividend will be paid on August 3, 2026, to shareholders of record as of the close of business on July 2, 2026.
Bristol Myers Squibb (NYSE:BMY) launched the “Investigating Myeloma” awareness campaign with actor and advocate Mariska Hargitay, honoring her father 20 years after his death from multiple myeloma.
The campaign highlights unmet needs in this incurable blood cancer and showcases BMS-led CELMoD targeted protein degradation research aimed at engaging cereblon to break down disease‑related proteins, stimulate the immune system, and enhance cancer cell killing.
Arcus Biosciences (NYSE:RCUS) entered a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE:BMY) to evaluate casdatifan, an investigational HIF-2a inhibitor, in the Phase 1/2 ROSETTA RCC-208 trial for advanced renal cell carcinoma.
Casdatifan will be added as two new trial arms in combination with pumitamig, an investigational PD-L1/VEGF-A bispecific antibody. Each company keeps development and commercial rights, and the agreement is mutually non-exclusive.
Bristol Myers Squibb (NYSE:BMY) and SystImmune reported prespecified interim Phase 3 results for izalontamab brengitecan (iza-bren) in triple-negative breast cancer (TNBC) and esophageal squamous cell carcinoma (ESCC).
Iza-bren improved overall survival, progression-free survival and objective response rates versus chemotherapy, with manageable safety, and an ESCC New Drug Application under priority review in China.